Eli Lilly has signed an oncology research collaboration and license agreement with Stipple Bio worth up to $5.9bn as it looks to bolster its precision cancer treatment pipeline.
Stipple Bio has developed a platform it calls Pointillist that identifies novel tumour-specific cell surface epitope binders. Epitopes are the antigen components that the immune system recognises and binds to with B cells, T cells, and proteins. Stipple’s aim is to develop powerful therapies that selectively target tumour cells, reducing on-target, off-tumour toxicity while increasing efficacy.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Neither Lilly nor Stipple disclosed how the $5.9bn was split, though the transaction involves the former making an upfront payment and equity investment into the biotech.
Stipple is also in line for research, product development and commercialisation milestones, as well as tiered royalties on product sales should Lilly successfully commercialise therapies from the collaboration. Lilly will attain worldwide rights to develop and commercialise any products arising from the pair-up.
Lilly said it would combine the biotech’s work with its proprietary oncology technologies to advance high therapeutic index compounds across multiple modalities.
Stipple stated it plans to initiate a Phase I clinical trial for an antibody-drug conjugate (ADC) in early 2027 for solid tumours, including pancreatic cancer.
Stipple’s CEO Jeff Landau said: “Stipple Bio was founded with the belief that epitope-level precision could distinguish tumour cells from healthy tissue, unlocking a new generation of effective and safer cancer therapies directed at targets whose expression on healthy cells has historically limited their clinical utility.”
The research agreement marks the second deal for Lilly this week, after it spent $1.5bn to acquire rare blood cancer biotech Calytrix Bio on 16 November.
It means Lilly has maintained a near-monthly M&A presence this year. The most expensive of these was the $7.8bn takeover of sleep drugmaker Centessa Pharmaceuticals in March.
